Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

#BIOCEO16 Session Recap: Regulatory Policy Outlook—PDUFA VI and You

CEO2013_115x75_Thumbnail copy

The second day of #BIOCEO16 kicked off this morning with a look ahead to PDUFA VI and potential ways to improve the drug development and approval process. Moderated by BIO Executive Vice President of Emerging Companies Cartier Esham, the panelists included: Elizabeth Krutoholow, Analyst, Bloomberg Intelligence Jonathan Leff, Partner, Deerfield Management; Chairman, Deerfield Institute Richard F. Pops, Chairman & Chief Executive Officer, Alkermes The challenges and opportunities presented by the growing amount of available “real Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIOCEO16 Fireside Chat with Senator Chuck Schumer

CEO2013_115x75_Thumbnail copy

New York Senator Chuck Schumer joined attendees at the 2016 BIO CEO & Investor Conference this afternoon for a fireside chat, moderated by BIO Chairman Ron Cohen, to discuss current political and public policy issues facing the country and the biopharmaceutical industry. The Senator expressed optimism that progress can be made on a bipartisan basis in a number of areas that will be conducive to investment in medical innovation and the well-paying jobs that such Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

Tomorrow: From Volume to Value: Designing a Patient-Centered Healthcare System (Webcast)

new-bio-logo

Tomorrow at the Newseum, The Hill will be hosting a live discussion about the transition from volume-based to value-based care. A live webcast will be available for the event, which begins at 8:30 am ET. Last week, Jim Robinson, President of Astellas Pharma US, shared his thoughts in a related op-ed at The Hill. Biopharmaceutical innovation is transforming what it means to be a patient battling some of our most difficult diseases, such as cancer, Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Senators Talent and Graham: Time to Act on Threat of Biological Terrorism

ebola

Last Friday in the St. Louis Post-Dispatch, Former Senators Jim Talent and Robert Graham wrote about the growing threat of biological attacks and threats and steps our nation can take to help prepare for them, including some of the recommendations in the report of the Blue Ribbon Study Panel on Biodefense, on which BIO President and CEO Jim Greenwood serves. The first step is to stockpile the medical countermeasures that will be necessary in the Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

Washington Post: Gene Therapies Offer “Dramatic Promise”

stethoscope

Yesterday’s Washington Post has an in-depth article about gene therapy, a type of therapeutic intervention which alters the underlying DNA responsible for producing certain diseases. The technology is enjoying a resurgence, fueled by some stunningly positive results in certain clinical trials recently. The authors begin with the story of 23 year old Allison Corona, who suffers from a congenital diseases that left her legally blind at age four. After receiving a gene therapy treatment: The world Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,